Company intelligence / Profile preview

Ventus Therapeutics

Waltham, Massachusetts, United Statesventustx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Ventus has advanced two lead programs from target screening to successful completion of Phase 1 trials within five years. VENT‑02 is now in a Phase 2 trial for Parkinson’s disease and will soon enter additional Phase 2 studies for osteoarthritis. VENT‑03 completed a successful Phase 1 trial with plans to enter Phase 2 for lupus in 2025. Both candidates have shown strong safety profiles and full target engagement at well-tolerated doses. The company also outlicensed VENT‑01 to Novo Nordisk for systemic inflammatory diseases.[6][10]

Therapeutic areas: ImmunologyNeurologyRheumatology
Modalities: Small molecules[1][3][5]
Industry: Biotech

Drug pipeline

3 assets

VENT-03

2 more assets in the full pipeline.

Request access →

Partnerships

Novo Nordisk — partnership on development of VENT‑01 for systemic inflammatory diseases.[3]

Beyond the preview

Go deeper on Ventus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ventus Therapeutics.

Explore the full profile